Le Lézard
Classified in: Health, Business
Subject: JVN

Pixie Dust Technologies, Inc. Announces Collaborative Research Agreement with Tohoku University School of Medicine


NEW YORK and TOKYO, Oct. 27, 2023 /PRNewswire/ - Pixie Dust Technologies, Inc. (Nasdaq: PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology, announced a joint research agreement with Tohoku University School of Medicine (the "University") for the purpose of developing and commercializing certain non-pharmaceutical skin disease treatments using wave control technology.

Since 2020, the Company has had an ongoing partnership with the University, combining the Company's wave control technology with University resources and knowledge. While the previous focus of this partnership was on a wide range of societal healthcare issues, today's agreement has the specific focus of pioneering an innovative, non-pharmaceutical approach to skin disease treatment using ultrasonic technology.

About Tohoku University

Name: National University Corporation Tohoku University
President: Hideo Ohno
Location: 2-1-1 Katahira, Aoba-ku, Sendai, Miyagi Prefecture
Established: June 1907
URL: https://www.tohoku.ac.jp/en/

Since its establishment in 1907, Tohoku University has been leading the way in the pursuit of truth, guided by its principles of 'Research First,' 'Open Doors,' and 'Practice Oriented Research and Education.' The University has produced many eminent leaders and achieved globally acclaimed research outcomes that have expanded the horizons of human knowledge and spearheaded transformation and innovation for future societies. In July 2020, the University updated the 'Vision 2030,' first laid out in 2018, and formulated the 'Connected University Strategy.' The University strongly promoted the digitalization of education, research, and co-creation with society, showcasing the roadmap towards a borderless, diverse, and truly inclusive university through the integrated use of cyberspace and physical spaces. In 2021, the University declared the 'Green Goals Initiative,' taking a new step toward creating a prosperous future. Moving forward, the University will continue to evolve alongside society as a comprehensive research university, addressing humanity's shared challenges such as the Sustainable Development Goals (SDGs), the Great Reset in the post- pandemic era, and achieving carbon neutrality, all grounded on solid research.

About Pixie Dust Technologies, Inc.

Pixie Dust Technologies, Inc. is a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology. The Company is currently focusing on two areas of product development: (1) "Personal Care & Diversity", where wave control technology is applied to mechanobiology and intervention/assistance in vision, hearing, and touch, and (2) "Workspace & Digital Transformation," where metamaterials (technology that creates properties through structure rather than material) and solutions to commercial design problems, such as in offices or construction sites, are applied.

SOURCE Pixie Dust Technologies


These press releases may also interest you

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...



News published on and distributed by: